At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 116 enrolled
Drug / intervention
Nivolumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single Arm, Open-Label Phase 2 Study of Nivolumab (BMS-936558) in Subjects With Relapsed or Refractory Follicular Lymphoma (FL)
In Brief
A Phase 2 clinical trial evaluating Nivolumab for Lymphoma. Completed, enrolled 116 participants across 45 sites in 12 countries.
Detailed Summary
The purpose of this study is to assess the clinical benefit of Nivolumab, as measured by independent radiologic review committee (IRRC)-assessed objective response rate (ORR) in subjects with FL lymphoma who have failed therapy with both CD20 antibody and an alkylating agent.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLymphoma
CountriesAustralia, Belgium, Canada, France, Germany, Italy, Norway, Singapore, Spain, Sweden, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJan 2014
Enrollment StartMar 2014
Primary CompletionMay 2017
Study CompletionDec 2020
TodayJul 2026
First PostedJan 17, 2014
Enrollment StartMar 26, 2014
Primary CompletionMay 17, 2017
Study CompletionDec 28, 2020
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 12.5 years ago
Interventions
Nivolumabdrug